Neutropenia - Pipeline Review, H1 2018

  • ID: 4482747
  • Drug Pipelines
  • 106 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Adello Biologics LLC
  • Biocon Ltd
  • Coherus BioSciences Inc
  • Lupin Ltd
  • Mycenax Biotech Inc
  • Sandoz International GmbH
  • MORE
Neutropenia - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia - Pipeline Review, H1 2018, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape.

Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Neutropenia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 2, 4, 8, 8, 1 and 2 respectively.

Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neutropenia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neutropenia (Hematological Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neutropenia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adello Biologics LLC
  • Biocon Ltd
  • Coherus BioSciences Inc
  • Lupin Ltd
  • Mycenax Biotech Inc
  • Sandoz International GmbH
  • MORE
Introduction

Report Coverage

Neutropenia - Overview

Neutropenia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Neutropenia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neutropenia - Companies Involved in Therapeutics Development

Adello Biologics LLC

Arven Ilac

BeyondSpring Pharmaceuticals Inc

Biocon Ltd

Cantex Pharmaceuticals Inc

Cellerant Therapeutics Inc

Chong Kun Dang Pharmaceutical Corp

Cleveland BioLabs Inc

Coherus BioSciences Inc

Dr. Reddy's Laboratories Ltd

Eurofarma Laboratorios SA

Ligand Pharmaceuticals Inc

Lupin Ltd

Merck & Co Inc

Mycenax Biotech Inc

Prolong Pharmaceuticals LLC

Richter Gedeon Nyrt

Sandoz International GmbH

USV Pvt Ltd

Neutropenia - Drug Profiles

ACN-8337 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARVMIC-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBLB-612 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dociparstat sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein for Neutropenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LG-7455 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nova-GM-CSF - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plinabulin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

posaconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romyelocel-L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamibarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UB-853 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neutropenia - Dormant Projects

Neutropenia - Discontinued Products

Neutropenia - Product Development Milestones

Featured News & Press Releases

Nov 30, 2017: European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon's Proposed Biosimilars Pegfilgrastim

Nov 07, 2017: Biocon: Resubmission of Pegfilgrastim Dossier with EMA

Sep 15, 2017: Mylan Announces Withdrawal of the marketing authorisation application for Fulphila (pegfilgrastim)

Sep 11, 2017: FDA Accepts Adello Biologics Biosimilar Biologics License Application for a Proposed Filgrastim Biosimilar

Jun 12, 2017: Coherus Biosciences Receives Complete Response Letter From FDA for Its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)

Apr 25, 2017: Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar

Jan 27, 2017: Withdrawal of the marketing authorisation application for Zioxtenzo (pegfilgrastim)

Dec 16, 2016: Withdrawal of the marketing authorisation application for Cavoley (pegfilgrastim)

Dec 16, 2016: Withdrawal of the marketing authorisation application for Efgratin (pegfilgrastim)

Nov 01, 2016: Prolong Pharmaceuticals Presents Data on Toxicology, Pharmacokinetics and Pharmacodynamics of ANF-RHO

Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (filgrastim) Patent Case

Jul 21, 2016: Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency

Jul 21, 2016: Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency

Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study

Mar 31, 2016: Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Neutropenia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Neutropenia - Pipeline by Adello Biologics LLC, H1 2018

Neutropenia - Pipeline by Arven Ilac, H1 2018

Neutropenia - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018

Neutropenia - Pipeline by Biocon Ltd, H1 2018

Neutropenia - Pipeline by Cantex Pharmaceuticals Inc, H1 2018

Neutropenia - Pipeline by Cellerant Therapeutics Inc, H1 2018

Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Neutropenia - Pipeline by Cleveland BioLabs Inc, H1 2018

Neutropenia - Pipeline by Coherus BioSciences Inc, H1 2018

Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2018

Neutropenia - Pipeline by Eurofarma Laboratorios SA, H1 2018

Neutropenia - Pipeline by Ligand Pharmaceuticals Inc, H1 2018

Neutropenia - Pipeline by Lupin Ltd, H1 2018

Neutropenia - Pipeline by Merck & Co Inc, H1 2018

Neutropenia - Pipeline by Mycenax Biotech Inc, H1 2018

Neutropenia - Pipeline by Prolong Pharmaceuticals LLC, H1 2018

Neutropenia - Pipeline by Richter Gedeon Nyrt, H1 2018

Neutropenia - Pipeline by Sandoz International GmbH, H1 2018

Neutropenia - Pipeline by USV Pvt Ltd, H1 2018

Neutropenia - Dormant Projects, H1 2018

Neutropenia - Dormant Projects, H1 2018 (Contd..1), H1 2018

Neutropenia - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Neutropenia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Adello Biologics LLC
  • Arven Ilac
  • BeyondSpring Pharmaceuticals Inc
  • Biocon Ltd
  • Cantex Pharmaceuticals Inc
  • Cellerant Therapeutics Inc
  • Chong Kun Dang Pharmaceutical Corp
  • Cleveland BioLabs Inc
  • Coherus BioSciences Inc
  • Dr. Reddy's Laboratories Ltd
  • Eurofarma Laboratorios SA
  • Ligand Pharmaceuticals Inc
  • Lupin Ltd
  • Merck & Co Inc
  • Mycenax Biotech Inc
  • Prolong Pharmaceuticals LLC
  • Richter Gedeon Nyrt
  • Sandoz International GmbH
  • USV Pvt Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll